SRC and non-small cell lung carcinoma: In an in vivo study, Masraksa et al. reported that through the elimination of focal adhesion formation and the inhibition of FAK–Src signaling, luteolin therapy prevented non-small cell lung cancer (NSCLC) from migrating.